MESO | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 9%

Liquidity 24%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

8.71%

1 Month

-5.54%

3 Months

-15.51%

6 Months

5.67%

1 Year

21.27%

2 Year

495.86%

Key data

Stock price

$15.85

P/E Ratio

0.00

DAY RANGE

$15.66 - $16.34

EPS

-$0.80

52 WEEK RANGE

$9.61 - $21.50

52 WEEK CHANGE

$21.27

MARKET CAP

769.562 M

YIELD

N/A

SHARES OUTSTANDING

114.178 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-28-2025

BETA

1.16

PUBLIC FLOAT

AVERAGE 10 VOLUME

$524,416

AVERAGE 30 VOLUME

$296,476

Company detail

CEO: Silviu Itescu
Region: US
Website: mesoblast.com
Employees: 80
IPO year: 2009

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Mesoblast Limited offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection. The company has strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd. and Grünenthal.

MESO - MESOBLAST LTD